Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 80Head & Neck 47Thoracic 29Gynecologic 13Genitourinary 6CNS 5Tumor-Agnostic 3Other neoplasm 3Lymphoid 2Breast 2Other solid neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Thrombocytopenia 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chemoradiotherapy × Classical hematology × Clear all
NCT05944809 2025-01-24

The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Completed
32 enrolled
Classical hematologyGastrointestinal

Esophageal Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡